All In Biotech

Drug Trial Radar · NCT05411016

A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus

A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose or Multiple Ascending Dose Study of KK4277 in Healthy Volunteers, Patient With Systemic Lupus Erythematosus, and Patient With Cutaneous Lupus Erythematosus

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

125

Actual

Start

Aug 3, 2022

Primary completion

Dec 10, 2024

Study completion Oct 27, 2025

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Part 1 : To evaluate the safety and tolerability of a single intravenous (IV) or subcutaneous (SC) dose of KK4277 in healthy Japanese or non-Asian adult males. Part 2 : To evaluate the safety and tolerability of repeated IV or SC administration of KK4277 in patients with Systemic lupus erythematosus (SLE) or Cutaneous lupus erythematosus (CLE).

Conditions

  • Healthy Volunteers
  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus (CLE)

Interventions

  • PlaceboDrug

    Placebo is administered single dose or multiple dose by IV or SC injection

  • KK4277Drug

    KK4277 is administered single dose or multiple dose by IV or SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Part 1 : from Day 1 through at most Day 113, Part 2: from Day 1 through at most Day 169

Locations

23 sites in 2 countries. Site status is shown where the registry gives one.

  • Fukushima Medical University Hospital

    Fukushima, Japan

  • Nagasaki University Hospital

    Nagasaki, Japan

  • Juntendo University Nerima Hospital

    Tokyo, Japan

  • Wakayama Medical University Hospital

    Wakayama, Japan

  • Fujita Health University Hospital

    Kutsukake, Aichi-ken, Japan

  • Japan Community Health care Organization Chukyo Hospital

    Minami, Aichi-ken, Japan

  • Juntendo University Urayasu Hospital

    Urayasu, Chiba, Japan

  • Kyusyu University Hospital

    Higashi, Fukuoka, Japan

  • Kanazawa University Hospital

    Kanazawa, Ishikawa-ken, Japan

  • Yokohama City University Medical Center

    Minami, Kanagawa, Japan

  • Kitasato University Hospital

    Minami, Kanagawa, Japan

  • National University Corporation Tohoku University Tohoku University Hospital

    Aoba, Miyagi, Japan

  • Niigata University Medical & Dental Hospital

    Chuo Ku, Niigata, Japan

  • University of the Ryukyus Hospital

    Ginowan, Okinawa, Japan

  • Saitama Medical University Hospital

    Moriyama, Saitama, Japan

  • Institute of Science Tokyo Hospital

    Bunkyō-Ku, Tokyo, Japan

  • St. Luke's International Hospital

    Chuo Ku, Tokyo, Japan

  • Showa Medical University East Hospital

    Shinagawa-Ku, Tokyo, Japan

  • Keio University Hospital

    Shinjuku-Ku, Tokyo, Japan

  • Japan Institute for Health Security National Center for Global Health and Medicine

    Shinjuku-Ku, Tokyo, Japan

  • Medical Co. LTA Sumida Hospital

    Sumida-ku, Tokyo, Japan

  • Seoul National University Hospital

    Seoul, South Korea

  • Ajou University Hospital

    Suwon, Gyeonggi-do, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.